Legacy Medical Device

What it is

Legacy Medical Device refers to a device legally placed on the market under prior rules that continues to be supplied during a defined transition to newer regulations. In the EU this typically means MDD/AIMDD or IVDD devices benefitting from MDR Art. 120 or IVDR Art. 110 transitional provisions as amended (e.g., Reg. (EU) 2023/607). In the U.S., the closest concept is a preamendments device—marketed before May 28, 1976 and unchanged—subject to later classification and controls (FD&C Act; FDA policy on preamendments devices). These devices remain lawful only if they meet strict conditions and ongoing oversight.

Regulatory framework

• EU (MDR): Transitional provisions for devices with valid MDD/AIMDD certificates and for Class I devices under certain conditions (MDR Art. 120; amended by Reg. (EU) 2023/607). Guidance clarifies expectations for “legacy devices,” surveillance, and documentation (MDCG 2021-25 Rev.1; MDCG 2022-4). :contentReference[oaicite:0]{index=0}
• EU (IVDR): Transitional provisions for IVDD devices placed on the market after IVDR DoA if Article 110 conditions are met; separate timelines apply (IVDR Art. 110; MDCG 2022-8). :contentReference[oaicite:1]{index=1}
• US (FDA): Preamendments devices were in commercial distribution before May 28, 1976; they may remain on the market until FDA requires PMA or other submissions through classification or reclassification processes (FDA “preamendments device” pages). :contentReference[oaicite:2]{index=2}

Key elements

• Status & scope: Clear identification as “legacy” (EU) or “preamendments” (US) with device codes, certificates, and applicable timelines.
• Ongoing conformity: Maintain QMS, vigilance, PMS/PSUR (EU), and labeling/UDI alignment during transition.
• Evidence currency: Clinical evaluation/performance eval remains required; justify that data remain sufficient for claims.
• Change control: Significant changes can end transitional status and trigger MDR/IVDR full compliance or new U.S. submissions.

Process — how it works

• 1) Confirm eligibility: Verify certificate validity and all Article 120/110 conditions (including no unacceptable risk and QMS in place by required dates). :contentReference[oaicite:3]{index=3}
• 2) Map timelines: Record device-specific deadlines from the applicable EU regulation or U.S. classification plan. :contentReference[oaicite:4]{index=4}
• 3) Maintain surveillance: Operate PMS, vigilance, and NB/authority oversight to the newer rules where required (e.g., MDR Chapter VII expectations for legacy devices). :contentReference[oaicite:5]{index=5}
• 4) Control changes: Assess any design, intended purpose, manufacturing, or labeling change; seek NB/FDA engagement when thresholds are met. :contentReference[oaicite:6]{index=6}
• 5) Transition plan: Build MDR/IVDR-compliant technical documentation or U.S. submissions in time to avoid supply gaps.

Common pitfalls

• Assuming “legacy” equals reduced requirements; many MDR/IVDR obligations still apply during transition. :contentReference[oaicite:7]{index=7}
• Missing new surveillance and reporting expectations for legacy devices, including NB oversight. :contentReference[oaicite:8]{index=8}
• Executing significant changes without prior assessment, which can terminate transitional use. :contentReference[oaicite:9]{index=9}
• Letting clinical or performance evidence go stale relative to current claims.

Quick checks / Tips

• Do you meet every condition in MDR Art. 120 or IVDR Art. 110 for continued supply? :contentReference[oaicite:10]{index=10}
• Is your PMS/PSUR or problem-reporting process aligned to current rules and NB/authority expectations? :contentReference[oaicite:11]{index=11}
• Have you documented a change policy that flags transitions to full MDR/IVDR or a new FDA filing?
• Are labeling, UDI, and databases consistent with the current regulatory status?